Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial in this in-depth interview.
Cummings, a professor of brain science and the director of the Chambers-Grundy Center for Transformative Neuroscience at University of Nevada–Las Vegas, and colleagues presented appropriate use criteria for the newly approved Biogen/Eisai agent at the 2021 Alzheimer’s Association International Conference.
Adolfo Ramirez-Zamora, MD; Joohi Jimenez-Shahed, MD; Aristide Merola, MD, PhD; and Michael J. Soileau, MD, discuss the challenges of starting a device-assisted therapy in patients with advanced Parkinson disease in episode 12 of the Peer Exchange series, "Recognizing and Managing Advanced Parkinson Disease."